The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Murphy, Daniel R ^a   Smolen, Lee J ^a   Klein, Timothy M ^a   Klein, Robert W ^a  

^a Medical Decision Modeling Inc   (United States)

Author keywords

Bisphosphonate; Cost effectiveness; Fractures; Glucocorticoid induced osteoporosis; Postmenopausal osteoporosis; Teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; SPINE FRACTURE; SWEDEN;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COSTS; FEMALE; GLUCOCORTICOIDS; HEALTH SERVICES; HUMANS; MALE; MODELS, ECONOMIC; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPINAL FRACTURES; SWEDEN; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867896789     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-213     Document Type: Article

References (30)

1. The societal burden of osteoporosis in Sweden. Borgström F, Sobocki P, Ström O, Jönsson B, Bone 2007 40 1602 1609 10.1016/j.bone.2007.02. 027 17433804 (Pubitemid 46766650)
2. Long-term risk of osteoporotic fracture in Malmö Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B, Osteoporos Int 2000 11 669 674 10.1007/s001980070064 11095169
3. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, Osteoporos Int 2008 19 399 428 10.1007/s00198-008-0560-z 18266020
4. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH, N Engl J Med 2001 344 1434 1441 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
5. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster J, Stepan JJ, Myers SL, Mitlak BH, Arch Intern Med 2004 164 2024 2030 10.1001/archinte.164.18.2024 15477438 (Pubitemid 39390560)
6. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH, J Bone Miner Res 2005 20 1507 1513 10.1359/JBMR.050501 16059622 (Pubitemid 41243539)
7. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH, Curr Med Res Opin 2005 21 1027 1034 10.1185/030079905X49671 16004669 (Pubitemid 41032691)
8. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R, N Engl J Med 2007 357 2028 2039 10.1056/NEJMoa071408 18003959 (Pubitemid 350106710)
9. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Orcel P, Joint Bone Spine 2005 72 461 465 10.1016/j.jbspin.2005.09.002 16326129 (Pubitemid 41821399)
10. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C, Rheumatology (Oxford) 2000 39 1383 1389 10.1093/rheumatology/39.12.1383 (Pubitemid 32045866)
11. Glucocorticoid-induced osteoporosis. Saag KG, Endocrinol Metab Clin North Am 2003 32 135 157 vii 10.1016/S0889-8529(02)00064-6 12699296 (Pubitemid 36378638)
12. TA161 Osteoporosis-secondary prevention including strontium ranelate: guidance. http://www.nice.org.uk/
13. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M, Health Technol Assess 2007 11 ii iv ix-xi, 1-231 18031652
14. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Lundkvist J, Johnell O, Cooper C, Sykes D, Osteoporos Int 2006 17 201 211 10.1007/s00198-005-1959-4 16027955 (Pubitemid 43053582)
15. TLV Historical Drug Prices. http://www.tlv.se/beslut/sok/lakemedel/
16. http://www.riksbanken.se; average rate ending December 2011 [www.riksbanken.se]
17. Sweden South Region Health Board Healthcare Region, Regional Rates and Allowances for Southern Health Region 2011 2010
18. Sweden Life Tables for 2003-2007. http://www.scb.se/
19. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B, Osteoporos Int 2005 16 15 25 10.1007/s00198-004-1688-0 15672210 (Pubitemid 40193215)
20. Mortality after osteoporotic fractures. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B, Osteoporosis International 2004 15 38 42 10.1007/s00198-003-1490-4 14593451 (Pubitemid 38252438)
21. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Lundberg L, Johannesson M, Isacson DGL, Borgquist L, Eur J Pub Health 1999 9 211 217 10.1093/eurpub/9.3.211 (Pubitemid 29448937)
22. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F, Calcif Tissue Int 2009 85 484 493 10.1007/s00223-009-9299-6 19823760
23. Compliance with drug therapy for postmenopausal osteoporosis. Weycker D, Macarios D, Edelsberg J, Oster G, Osteoporos Int 2006 17 1645 1652 10.1007/s00198-006-0179-x 16862397 (Pubitemid 44477625)
24. The components of excess mortality after hip fracture. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK, Bone 2003 32 468 73 10.1016/S8756-3282(03)00061-9 12753862 (Pubitemid 39665705)
25. Quality of life in patients with osteoporosis. Lips P, van Schoor NM, Osteoporos Int 2005 16 447 455 10.1007/s00198-004-1762-7 15609073
26. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Schousboe JT, Curr Rheumatol Rep 2007 9 50 56 10.1007/s11926-007-0022-1 17437668 (Pubitemid 46806308)
27. CPI Historical numbers, 1830. Statistics Sweden, http://www.scb.se/Pages/ TableAndChart-33896.aspx
28. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Schousboe JT, Nyman JA, Kane RL, Ensrud KE, Ann Intern Med 2005 142 734 741 15867405 (Pubitemid 40593775)
29. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O, J Med Econ 2010 13 381 392 10.3111/13696998.2010.499072 20604678
30. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Peasgood T, Herrmann K, Kanis JA, Brazier JE, Osteoporos Int 2009 20 853 868 10.1007/s00198-009-0844-y 19271098